Isomorphic Labs raises $5 billion: the terms and the path to clinical trials
Isomorphic's Series C is its second large round in about six months and lifts its disclosed external funding to $7.7 billion. The company names its investors and spending priorities. It does not name a valuation, a drug candidate or a date for its first clinical trial, a target that has already moved once.
Isomorphic Labs, the drug-design company founded by Demis Hassabis in 2021, said on 17 November 2026 that it has raised $5 billion in a Series C round co-led by Greenoaks and Sequoia Capital. Andreessen Horowitz joined as a new investor, Alphabet made what the company calls “continued significant investment,” and every existing investor took part. The round comes 189 days after Isomorphic announced a $2.1 billion Series B, and it brings the company’s announced external funding to $7.7 billion in under 20 months. The most useful fact for anyone weighing the number is what the release leaves out: it gives no valuation, names no drug candidate and sets no date for a first clinical trial. Isomorphic says its preclinical results are “setting the stage for clinical entry.” It has not announced a clinical trial.
This account is built from Isomorphic’s releases and posts and the 5 August 2026 messages from Sundar Pichai and Hassabis on Hassabis’s roles at Google. Details the company has not confirmed, such as the valuation and Hassabis’s comments to Bloomberg, are attributed to the outlets that published them. The Frontier Wire has not tested Isomorphic’s models or seen data on its drug programmes.
TL;DR
- Isomorphic raised $5 billion in a Series C co-led by Greenoaks and Sequoia Capital, with a16z new and Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also in. The release calls the round oversubscribed.
- No valuation was disclosed. Bloomberg reported on 4 November that the company was in talks to raise about $5 billion at about $50 billion.
- The money is earmarked for the IsoDDE design engine, new biology models, a partner ecosystem, “AI-led bioengineering” infrastructure and clinical development infrastructure.
- No trial has been announced. Hassabis targeted trials by the end of 2025, then by the end of 2026, and in an interview Bloomberg published on 17 November 2026 declined to give a new date, according to Quartz and The Next Web.
- Hassabis remains Isomorphic’s CEO. In August he gave up day-to-day leadership of Google DeepMind to become its Chair and Alphabet’s Chief Scientist.
What Isomorphic announced
The announcement on Isomorphic’s site is short. The details are in a three-page news release dated “LONDON, 17 November, 2026.” Its subheading says Greenoaks and Sequoia Capital “co-lead the oversubscribed round.” The body text names the participants in three groups: the co-leads with “Andreessen Horowitz (a16z) and several other new investors”; Alphabet, with “continued significant investment”; and “all existing investors: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund.”
| Term | What the release says | What it does not say |
|---|---|---|
| Amount | $5 billion, Series C | How it splits between equity tranches or investors |
| Leads | Greenoaks and Sequoia Capital, co-leading | Each lead’s commitment |
| New investors | Andreessen Horowitz and “several other new investors” | Names of the other new investors |
| Alphabet | “Continued significant investment” | Amount or resulting stake |
| Existing investors | All took part: Thrive Capital, MGX, GV, CapitalG, Temasek, UK Sovereign AI Fund | Their amounts |
| Valuation | Not stated | Pre-money or post-money figure |
| Demand | Round described as “oversubscribed” | How much demand exceeded the raise |
Two of the existing investors are Alphabet’s own funds. GV is Alphabet’s venture arm and CapitalG its growth fund, so Alphabet money reaches the round through three channels. The release does not say what share of the $5 billion they supplied.
Four people are quoted. Hassabis, described as “Founder and CEO of Isomorphic Labs,” says the round lets the company focus on “building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.” Max Jaderberg, the company’s President, says: “Every week we are making repeatable scientific advancements enabled by our models.” Neil Mehta, Founder and Managing Partner of Greenoaks, calls drug development “an optimization challenge of almost infinite scale.” Konstantine Buhler, a Partner at Sequoia Capital, says he is inspired to see the team “translate advanced AI into a growing portfolio of drug candidates.”
None of the quotes gives a number for the pipeline, a target name or a date.
Three rounds in under 20 months
Isomorphic described its March 2025 raise as “its first external funding round.” Before that, it was funded by Alphabet without an announced round. The three external rounds since then have each been larger than the last, and the investor list has grown each time.
| Round | Date announced | Amount | Led by | Other named participants | Stated use |
|---|---|---|---|---|---|
| First external round | 31 March 2025 | $600 million | Thrive Capital | GV; follow-on from Alphabet | AI drug design engine research; advance “our own programs into clinical development”; hiring |
| Series B | 12 May 2026 | $2.1 billion | Thrive Capital | Alphabet and GV; new: MGX, Temasek, CapitalG, UK Sovereign AI Fund | Develop and deploy IsoDDE; move pipeline “towards the clinic”; hiring “AI, engineering, drug design, and clinical talent” |
| Series C | 17 November 2026 | $5 billion | Greenoaks and Sequoia Capital | a16z and other new investors; Alphabet; all existing investors | IsoDDE and new biology models; partner ecosystem; “AI-led bioengineering” infrastructure; translational and clinical development infrastructure |
The arithmetic is The Frontier Wire’s. The three rounds total $7.7 billion. The two rounds in 2026 total $7.1 billion and came 189 days apart. The Series C alone is more than twice the Series B and more than eight times the first round.
The language around the clinic has shifted across the three releases, and the shift is worth reading closely. In March 2025, Hassabis said the money would “help us advance our own programs into clinical development.” In May 2026 the release spoke of “accelerating and expanding its pipeline of therapeutic programs towards the clinic.” In November 2026 the release says proceeds will support “scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.” Each round has been raised with the clinic as a stated next step. None has been raised on a completed clinical milestone.
Valuation: reported, not disclosed
Isomorphic did not state a valuation in its release, and TechCrunch, Quartz and The Next Web all report that the company did not disclose one. The figures in circulation come from Bloomberg, in two stages.
On 8 October 2026, Bloomberg reported that Isomorphic was “in early talks to raise new funds at a valuation of at least $40 billion, according to people familiar with the matter,” and that it could be valued “at as much as $50 billion, one of the people said.” The publicly visible part of that report gave no round size or investors, and said Isomorphic did not respond to a request for comment.
On 4 November 2026, Bloomberg reported, again citing people familiar with the matter, that the company was in talks to raise about $5 billion at a valuation of about $50 billion. The Next Web relayed that report and said it had not verified it independently; it named no investors.
The $5 billion figure from 4 November matches the amount announced on 17 November. That match makes the report more credible but does not confirm its valuation, and Bloomberg itself reported on 17 November, according to Quartz and The Next Web, that Isomorphic would not reveal what it is worth. Readers should treat “about $50 billion” as a reported price, not a disclosed one. Isomorphic has never publicly stated a valuation for any of its three rounds.
CNBC put the round in a wider context, citing data from the deal-counting platform Dealroom that drug discovery startups had raised $23.2 billion in 2026, which it called a record. If that figure includes the Series C, Isomorphic’s two rounds this year account for nearly a third of it. That share is The Frontier Wire’s arithmetic on Dealroom’s total, and CNBC does not say whether the total includes the 17 November round.
Where the money goes
The release lists five uses for the money. It gives no split between them.
- Maturing IsoDDE. The company “will continue to mature IsoDDE,” its proprietary drug design engine, which the release describes as unifying “a suite of foundational simulation AI models that natively work across multiple therapeutic areas and drug modalities.”
- New biology models. It will “expand deeper into new biology with highly advanced models.”
- A partner ecosystem. To deliver “new and transformative classes of therapeutics,” Isomorphic says it “is creating a partner ecosystem to advance the understanding of mechanistic disease biology.”
- Bioengineering infrastructure. “In parallel, the company is building the global infrastructure required to power the future of AI-led bioengineering.” The release does not say whether this means compute, wet labs, data generation or all three.
- Clinical development. Proceeds will “support the company’s continued build of scalable AI-first translational and clinical development infrastructure as it advances its drug candidates to clinical trials.”
Two of these are new compared with the Series B. The May release did not mention a partner ecosystem for disease biology or global bioengineering infrastructure. Both point beyond designing molecules toward generating biological data and understanding disease mechanisms, which is consistent with Isomorphic’s decision in October to join the Virtual Biology Initiative as a founding member (covered below).
The September essay on Isomorphic’s site, “Building a new path to make medicines with AI,” describes the company’s intended shape in more detail. It calls Isomorphic “a vertically integrated company” that will “develop the AI models, generate the data, discover new biology, and then will take those potential medicines to patients in the clinic.” It describes a target modality range “from small molecules to antibodies, peptides, and beyond.” The Series C use-of-funds list reads as a plan to build each of those layers at once.
The pipeline: what is public
Isomorphic says it is “advancing a broad and ambitious drug design portfolio through partnered programs and wholly-owned internal programs.” It has never named a target or a candidate from its internal programmes. What is on the record is the therapeutic focus, the partners and the company’s characterisation of its own results.
The internal programmes were described in March 2025 as “primarily focused in oncology and immunology.” The Series C release says the work “is yielding positive preclinical results, both for internal programs in oncology and immunology and with partners.” It does not describe the results, the number of programmes or the stage each has reached. Bloomberg reported on 17 November, according to Quartz and The Next Web, that Isomorphic has more than 20 programmes under way, a count the company’s release does not include.
| Partner | Announced | Scope, per Isomorphic | Disclosed economics |
|---|---|---|---|
| Eli Lilly | January 2024 | Small molecule therapeutics against “a number of undisclosed targets” | $45 million upfront |
| Novartis | January 2024; expanded February 2025 | Small molecules against three “particularly challenging targets,” expanded by “up to three additional research programs” | $37.5 million upfront |
| Johnson & Johnson (Janssen Biotech) | 20 January 2026 | “Cross-modality, multi-target” collaboration, including large molecule and biologics design | Not disclosed |
| Virtual Biology Initiative (Biohub-convened) | 7 October 2026 | Founding member of an effort to generate open, AI-ready biological data | Google DeepMind, Isomorphic and Meta together investing $300 million; individual shares not stated |
Isomorphic said in January 2024 that the Lilly and Novartis collaborations together “have the potential to be worth nearly $3 billion to Isomorphic Labs, excluding any royalties,” with “a combination of upfront and milestone payments.” The headline upfront figures are $45 million from Lilly and $37.5 million from Novartis. The remainder depends on milestones that have not been reported as reached.
The Johnson & Johnson release sets out a division of labour that matters for how to read “partnered” progress. “Isomorphic Labs will be responsible for in silico predictions and design while Johnson & Johnson will conduct experimental assays and assume responsibility for advancing programs.” In that collaboration, at least, a partnered molecule that reaches the clinic would be advanced by Johnson & Johnson, not by Isomorphic.
The Virtual Biology Initiative release, issued from Redwood City by Biohub and partners, describes a combined commitment of $1.8 billion “in funding, data, computation, and new measurement technology” from Biohub, the US Department of Energy, the National Institutes of Health and new funding partners. Jaderberg is quoted there saying the initiative will “generate the data needed to push the industry closer to the next significant breakthrough for biology.”
For a sense of what the published record does and does not support, the site’s map of evidence levels in AI for biology is a useful frame. Isomorphic’s public evidence today sits at computational benchmarks and the company’s own descriptions of wet-lab results. It has not reached the clinical rungs.
The clinical-trial timeline, statement by statement
The question investors and patients will ask is when an Isomorphic-designed drug enters a human trial. The public target has moved once, from the end of 2025 to the end of 2026, and the latest statement sets no date. The sequence is worth setting out in full.
| Date | Statement | Source |
|---|---|---|
| 21 January 2025 | Hassabis, at a World Economic Forum panel in Davos, expects “some AI-designed drugs in clinical trials by the end of the year” | The Register |
| 31 March 2025 | Funding will “help us advance our own programs into clinical development” | Isomorphic release |
| 20 January 2026 | Hassabis, at Davos, says Isomorphic expects its first clinical trials by the end of 2026 | Reuters (paraphrase) |
| 12 May 2026 | Series B will accelerate the pipeline “towards the clinic” | Isomorphic release |
| 27 May 2026 | Hassabis: “we’re in pre-clinical with a bunch of our programs, and it’s going very well”; no trial timeline given | Fortune |
| 29 September 2026 | “Our preclinical data is helping us to gear up for clinical developments” | Isomorphic essay |
| 17 November 2026 | Preclinical results “setting the stage for clinical entry”; capital to advance candidates “to clinical trials” | Isomorphic release |
| 17 November 2026 | Hassabis declines to give a revised target; says regulatory submissions are on track and more will be announced in 2027 | Bloomberg, as relayed by Quartz and The Next Web |
The end-of-2025 target was missed. Reuters reported the end-of-2026 target in January as a delay from the earlier goal. As of 18 November 2026, 43 days remain in the year.
The Bloomberg interview is the most recent statement and the least precise. According to both Quartz and The Next Web, Hassabis would not give Bloomberg an updated target and said the company would have more to announce in 2027. Quartz’s account says he described regulatory filings for the first oncology programme as progressing as planned; The Next Web’s says the company is on track with regulatory submissions. Neither outlet quotes him directly on the timeline, and The Frontier Wire could not read Bloomberg’s article. A regulatory submission, such as an application to begin human testing, is a step before a trial starts, not evidence that one has.
The Frontier Wire searched ClinicalTrials.gov, the US registry, on 18 November 2026 for studies with Isomorphic Labs as sponsor or anywhere in the record. Both searches returned no studies. That is consistent with the company’s own wording, though it is not conclusive on its own: a trial can be registered after it begins, can be registered in another country’s registry, and a partnered molecule could be registered under the partner’s name.
The defensible summary is that Isomorphic has not announced a trial, the registry shows none, the company’s year-end target has not been publicly withdrawn but has not been reaffirmed either, and the next concrete news is promised for 2027.
The engine behind the pitch
Isomorphic’s case to investors rests on IsoDDE, the Isomorphic Labs Drug Design Engine. The company introduced it in a technical post and report it dates to February 2026, which preview “a subset” of its capabilities. All of the following are Isomorphic’s claims about its own system, measured by Isomorphic.
- Structure prediction on unfamiliar systems. On the Runs N’ Poses benchmark, which tests generalisation to protein pockets and ligands unlike those in the training data, Isomorphic says IsoDDE “more than doubles the accuracy of AlphaFold 3 on the most difficult systems.”
- Antibodies. On “a challenging, novel antibody-antigen test set” of 334 cases, Isomorphic says IsoDDE outperforms AlphaFold 3 by 2.3 times and Boltz-2 by 19.8 times in the high-accuracy band (DockQ above 0.8).
- Binding affinity. Isomorphic says IsoDDE “surpasses all deep-learning methods by a considerable margin” on three public benchmarks (FEP+ 4, OpenFE and the CASP16 blind binding affinity task) and can surpass physics-based free-energy methods.
- Pocket finding. Isomorphic says IsoDDE recovered a cryptic, allosteric binding pocket on the protein cereblon, reported in a 2026 experimental study (Dippon et al.), from the amino acid sequence alone.
The September essay adds a description of a design agent that runs autonomously for two to four days against a specification (target, modality, selectivity and properties such as solubility), followed by synthesis and lab testing of a handful of selected compounds. It shows one example and says it is “one example of dozens.” It does not name the target.
Benchmarks of this kind measure prediction accuracy, which is necessary but far from sufficient for a medicine. A better pose or affinity estimate shortens the path to a lab-validated hit. It says nothing yet about toxicity in humans, dosing or efficacy, which only trials can establish. The site’s report on Google’s agent-assisted wet-lab work draws the same line between molecular search and experimental validation in a neighbouring setting.
Leadership: what changed for Hassabis
Some reports have described Hassabis as having left Google DeepMind to focus on drug discovery. The primary record is more specific than that.
On 5 August 2026, Google published two internal messages under the title “The next chapter of our AI momentum.” In the first, Sundar Pichai, CEO of Google and Alphabet, wrote that he and Hassabis had “been long discussing a role that allows him to put his full attention on actively shaping the future of AGI.” He continued: “Demis will become the Chair of GDM and Chief Scientist of Alphabet, while continuing to lead Isomorphic Labs.” Koray Kavukcuoglu, then Google DeepMind’s Chief Technology Officer and Google’s Chief AI Architect, “will step up as SVP of Google DeepMind, reporting to me,” Pichai wrote, overseeing Gemini model development, frontier AI research and the Gemini app and developer teams.
In the second message, Hassabis wrote that he had “decided that now is the right time for me to hand over my day-to-day operational responsibilities at GDM.” He described the new position as “a new strategic role as Chair of GDM and Chief Scientist of Alphabet.” On Isomorphic, he wrote: “As part of this transition, I’ll also be leaning into my role at Isomorphic, where we are making extremely rapid and promising progress, to accelerate our mission there even faster.”
So the precise account is this. Hassabis gave up running Google DeepMind day to day. He did not leave Google or Alphabet: he holds two Alphabet titles, and Google’s blog now lists him as “Chair, Google DeepMind and Chief Scientist, Alphabet.” Pichai’s stated reason for the change was AGI, not drug discovery. Isomorphic was named in both messages as a continuing role that Hassabis intended to spend more time on. He is described in the Series C release, as in the two earlier funding releases, as founder and CEO.
| Person | Role | Since, per primary sources |
|---|---|---|
| Demis Hassabis | Founder and CEO, Isomorphic Labs; Chair, Google DeepMind; Chief Scientist, Alphabet | Isomorphic since its 2021 founding; Google roles from 5 August 2026 |
| Max Jaderberg | President, Isomorphic Labs | January 2026, per Isomorphic’s November 2025 interview with him as “incoming President” |
| Koray Kavukcuoglu | SVP, Google DeepMind and Chief AI Architect, Google | SVP role from 5 August 2026 |
| Ben Wolf | Chief Medical Officer, Isomorphic Labs | Introduced in June 2025; formerly CMO at Relay Therapeutics; tasked with setting up the US presence in the Boston area |
| Sarah Skerratt | Chief Research Officer, Isomorphic Labs | Quoted in this role in the January 2026 Johnson & Johnson release |
The operating structure under Hassabis matters for reading the round. Jaderberg, a founding team member whose earlier reinforcement learning work at DeepMind included Capture the Flag and AlphaStar, according to Isomorphic, told Isomorphic in November 2025 that his focus as President would be “progressing our internal and partnership programmes towards the clinic, scaling and refining new generations of our drug design engine.” The clinical build-out sits with Wolf, who described his career as taking medicines “through the process of human testing, proof of concept and ultimately registration.” The Series C quotes Hassabis and Jaderberg side by side, and Greenoaks’ Mehta names both: “We believe Demis, Max, and the Isomorphic team are building the future of AI-led drug discovery.”
The investors and what their presence signals
The investor list has changed character across the three rounds. The first round was Thrive Capital, GV and Alphabet. The Series B added sovereign and state-linked capital: MGX, Temasek and the UK Sovereign AI Fund, alongside CapitalG. The Series C adds two large generalist growth investors as co-leads, Greenoaks and Sequoia Capital, and a16z.
The release does not say why Thrive, which led both earlier rounds, did not lead this one, and it would be speculation to explain it. What can be said is that every prior investor came back. Thrive’s chief executive, Joshua Kushner, said in May that “our conviction in the team has only deepened.” Ruth Porat, President and Chief Investment Officer of Alphabet and Google, said in May that the funding “will be used to accelerate the work and bring important interventions to market with greater speed.”
Sequoia has a prior public connection to the company: Isomorphic’s site hosts a podcast episode, dated 29 April 2025, in which Jaderberg was interviewed by Stephanie Zhan of Sequoia Capital when he was Isomorphic’s Chief AI Officer. That is a public relationship, not evidence of any term in the round.
Alphabet’s position is the one most worth watching and the least visible. It funded Isomorphic before any external round, has invested in every round since, and participates through GV and CapitalG as well as directly. None of the releases gives Alphabet’s stake.
What remains unknown
The release and the reporting around it leave several material questions open.
- Valuation and ownership. No valuation, no share of the company held by Alphabet, and no amount from any single investor.
- The candidates. No target, no molecule, no indication beyond “oncology and immunology,” and no count of programmes from the company itself. The “more than 20” figure is Bloomberg’s report.
- The first trial. No date, no country, no indication, and no statement on whether the first trial will be an internal or partnered programme.
- The preclinical data. “Positive preclinical results” are asserted, not shown. No data has been published on an Isomorphic drug candidate.
- The infrastructure. The “AI-led bioengineering” infrastructure is not defined (see above).
- Partner milestones. Whether any Lilly or Novartis milestone payment has been triggered has not been disclosed.
- IsoDDE’s full capabilities. The technical report covers “a subset” of the engine. No external group has reported reproducing its results, and the full system is not available to outside researchers.
Evidence that would change this assessment includes a registered trial, a named candidate with published preclinical data, a disclosed valuation or a partner announcing that an Isomorphic-designed molecule has entered development.
What the round establishes
The $5 billion establishes that large growth investors are prepared to put billions into Isomorphic before it has a drug in the clinic. It establishes that Alphabet is still putting money in. And it establishes Isomorphic’s own description of its next step: the release mentions clinical trials or clinical entry three times.
It does not establish that the platform produces better medicines, faster, than conventional discovery. That claim can only be tested in trials, and the company’s public timeline for the first one has already moved once. The most specific forward-looking statement now on record is Bloomberg’s account that Hassabis expects more news in 2027. Until then, the precise reading of 17 November is that Isomorphic raised a very large sum on the strength of its models, its partners and its leadership, and that the evidence from patients is still to come.
Sources
- Isomorphic Labs: Isomorphic Labs announces Series C investment round (17 November 2026)
- Isomorphic Labs: Series C news release, PDF (17 November 2026)
- Isomorphic Labs: Isomorphic Labs announces Series B investment round (12 May 2026)
- Isomorphic Labs: Series B news release, PDF (12 May 2026)
- Isomorphic Labs: $600 million external investment round, news release PDF (31 March 2025)
- Isomorphic Labs: The Isomorphic Labs Drug Design Engine unlocks a new frontier
- Isomorphic Labs: Building a new path to make medicines with AI (29 September 2026)
- Isomorphic Labs: Partnerships
- Isomorphic Labs: Isomorphic Labs kicks off 2024 with two pharmaceutical collaborations
- Isomorphic Labs: Research collaboration with Johnson & Johnson, news release PDF (20 January 2026)
- Biohub and partners: Virtual Biology Initiative expansion, news release PDF (7 October 2026)
- Isomorphic Labs: In conversation with Max Jaderberg, incoming President (26 November 2025)
- Isomorphic Labs: In conversation with Dr Ben Wolf, new Chief Medical Officer (17 June 2025)
- Google: The next chapter of our AI momentum, messages from Sundar Pichai and Demis Hassabis (5 August 2026)
- Bloomberg via Bloomberg Government: Isomorphic Labs in funding talks for over $40 billion value (8 October 2026)
- The Next Web: Isomorphic Labs in talks to raise $5bn at a $50bn valuation, Bloomberg reports (5 November 2026)
- Quartz: Alphabet's Isomorphic Labs raised $5 billion in Series C funding for AI drug design (17 November 2026)
- The Next Web: Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design (17 November 2026)
- TechCrunch: Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials (17 November 2026)
- CNBC: Demis Hassabis' AI company raises $5 billion, months after he left as Google DeepMind CEO (17 November 2026)
- Reuters via Investing.com: Google-backed Isomorphic Labs delays clinical trial timeline (20 January 2026)
- The Register: Google DeepMind CEO says 2025's the year we start popping pills AI helped invent (22 January 2025)
- Fortune Term Sheet: Demis Hassabis on his rush to solve all disease and Isomorphic's new $2.1 billion (27 May 2026)
- Isomorphic Labs: The Quest to 'Solve All Disease' with AI, podcast with Max Jaderberg hosted by Sequoia Capital's Stephanie Zhan (29 April 2025)
- ClinicalTrials.gov: study search API
Questions readers ask
How much has Isomorphic Labs raised from outside investors?
Isomorphic has announced three external rounds: $600 million in March 2025, $2.1 billion in May 2026 and $5 billion on 17 November 2026. That adds up to $7.7 billion, by The Frontier Wire's arithmetic. Alphabet's funding before March 2025 was not announced as a round.
What is Isomorphic Labs valued at?
The company has not disclosed a valuation. Bloomberg, citing people familiar with the matter, reported on 4 November 2026 that Isomorphic was in talks to raise about $5 billion at a valuation of about $50 billion. That figure is reported, not confirmed by the company.
Does Isomorphic Labs have a drug in clinical trials?
Not according to its own announcement. The 17 November release describes positive preclinical results in oncology and immunology that are 'setting the stage for clinical entry.' A search of ClinicalTrials.gov on 18 November 2026 returned no study naming Isomorphic Labs.
Did Demis Hassabis leave Google DeepMind to run Isomorphic?
Not exactly. On 5 August 2026 he handed day-to-day running of Google DeepMind to Koray Kavukcuoglu and became Chair of Google DeepMind and Chief Scientist of Alphabet. Sundar Pichai said the new role lets him focus on AGI. Hassabis said he would also lean further into Isomorphic, where he remains CEO.
Did The Frontier Wire verify Isomorphic's scientific claims?
No. The claims about IsoDDE's accuracy and the preclinical results are Isomorphic's own. The company has not published data on individual drug candidates, and The Frontier Wire has not tested its models.
